Astellas rejoins the autoimmune antibody craze with Pandion partnership
Over a year ago, Astellas CEO Kenji Yasukawa announced a large R&D restructure: 600 cut jobs, multiple research subsidiaries shut down, and a rejiggered early pipeline approach centered on so-called “focus areas.” Each focus area was detailed briefly in a report they released, along with how they’d reach the therapy.
But one sub-focus area looked different. Rather than list the features of their technology, the space below auto-antibodies (a form of autoimmune disorder) said simply “development of new platform.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters